Previous 10 | Next 10 |
Can-Fite Signed agreement with Fondazione Telethon for co-development of Piclidenoson for the treatment of Lowe syndrome an estimated $100 M market in the U.S. only with no drug available FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number...
2023-08-18 08:09:47 ET More on Can-Fite Biopharma Can-Fite's Namodenoson shows promising results in preclinical study on pancreatic carcinoma, shares rise 11% Can-Fite stock rises after discovering effect of Namodenoson in pancreatic cancer Can-Fite gains on EU nod t...
FDA encouraged the Company to enroll adolescent patients due to Piclidenoson’s good safety profile There is an unmet need for safe, convenient, and effective drugs to treat chronic plaque psoriasis in the adolescents Can-Fite BioPharma Ltd . (NYSE American: CA...
Can-Fite’s novel approach for the treatment of advanced liver cancer will be presented at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting in Japan on August 4 th 2023 Namodenoson is in pivotal Phase 3 study for the treatment of advanced hepatoc...
2023-06-29 08:29:48 ET Eco Wave Power ( WAVE ) +56% . RenovoRx ( RNXT ) +24% . Kintara Therapeutics ( KTRA ) +22% . Intelligent Living Application ( ILAG ) +15% . Joby Aviation ( JOBY ) +14% rallies 10% to new 52-week h...
FDA encouraged the Company to enroll adolescent patients due to the strong safety profile of the drug demonstrated over the development history and prior clinical studies Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of...
2023-06-13 08:01:52 ET Can-Fite BioPharma ( NYSE: CANF ) said it is preparing to submit an Investigational New Drug ( IND ) application to the US FDA for its pancreatic cancer candidate namodenoson. The Israeli biotech's stock is up 6% in premarket trading. With ...
Namodenoson’s robust effect reached 90% inhibition of pancreatic cancer growth in pre-clinical studies Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflam...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced its VP of Business Development, Dr. Sari Fishman, will participate in numerous par...
2023-06-01 07:07:56 ET Can-Fite Biopharma press release ( NYSE: CANF ): Q1 GAAP EPS of $0.00. Revenue of $0.2M (flat Y/Y). For further details see: Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...